28 May 2026
NuVision Biotherapies, an optics tissue-therapy company, has appointed Tim Precious as its new chief executive officer.
Precious took on the role from 26 May, with a remit to lead the execution of the company’s commercial strategy and optimise go-to-market activity across healthcare sectors.
Precious has spent the majority of his career at EssilorLuxottica in roles across the UK and Ireland, Nordics, and Benelux, most recently serving as general manager for UK and Ireland.
With extensive leadership experience in the optical and ophthalmic space, he has led businesses from £35m to £250m in turnover and teams of up to 450 people, including navigating post-acquisition transformation.
Commenting on his appointment, Precious said: “Having spent my career in the optical and ophthalmic sector, I know first-hand the difference that innovative products can make for patients and clinicians alike.”
“This business has done the hard work of building something genuinely differentiated, and I’m looking forward to translating that clinical excellence into further commercial success,” he added.
NuVision Biotherapies said the appointment marks a significant milestone as it transitions from a research and development (R&D) led business to a “commercially focused organisation” expanding across the UK, Middle East, Nordics, and central Europe.
Roger Teasdale, chairman at NuVision, said: “As we move from a R&D focus to commercialisation, we need a leader who has operated at scale across the markets we are targeting.”
Teasdale added that Precious’ “breadth of experience and enduring focus on customers and teams” means he is ideally placed to lead the company through its next chapter.
The company noted that the two appointments offer strategic coverage of key markets, with Underhill bringing experience in the Middle East, complementing Precious’ knowledge of the UK and Ireland and continental Europe.
Comments (0)
You must be logged in to join the discussion. Log in